| Title: | PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma |
| Authors: | Maekawa, Naoya Browse this author |
| Konnai, Satoru Browse this author →KAKEN DB |
| Nishimura, Maki Browse this author |
| Kagawa, Yumiko Browse this author |
| Takagi, Satoshi Browse this author |
| Hosoya, Kenji Browse this author →KAKEN DB |
| Ohta, Hiroshi Browse this author |
| Kim, Sangho Browse this author |
| Okagawa, Tomohiro Browse this author →KAKEN DB |
| Izumi, Yusuke Browse this author |
| Deguchi, Tatsuya Browse this author |
| Kato, Yukinari Browse this author |
| Yamamoto, Satoshi Browse this author |
| Yamamoto, Keiichi Browse this author |
| Toda, Mikihiro Browse this author |
| Nakajima, Chie Browse this author →KAKEN DB |
| Suzuki, Yasuhiko Browse this author →KAKEN DB |
| Murata, Shiro Browse this author →KAKEN DB |
| Ohashi, Kazuhiko Browse this author →KAKEN DB |
| Issue Date: | 12-Feb-2021 |
| Publisher: | Nature Research |
| Journal Title: | NPJ precision oncology |
| Volume: | 5 |
| Issue: | 1 |
| Start Page: | 10 |
| Publisher DOI: | 10.1038/s41698-021-00147-6 |
| Abstract: | Immunotherapy targeting programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1) represents promising treatments for human cancers. Our previous studies demonstrated PD-L1 overexpression in some canine cancers, and suggested the therapeutic potential of a canine chimeric anti-PD-L1 monoclonal antibody (c4G12). However, such evidence is scarce, limiting the clinical application in dogs. In the present report, canine PD-L1 expression was assessed in various cancer types, using a new anti-PD-L1 mAb, 6C11-3A11, and the safety and efficacy of c4G12 were explored in 29 dogs with pulmonary metastatic oral malignant melanoma (OMM). PD-L1 expression was detected in most canine malignant cancers including OMM, and survival was significantly longer in the c4G12 treatment group (median 143 days) when compared to a historical control group (n=15, median 54 days). In dogs with measurable disease (n=13), one dog (7.7%) experienced a complete response. Treatment-related adverse events of any grade were observed in 15 dogs (51.7%). Here we show that PD-L1 is a promising target for cancer immunotherapy in dogs, and dogs could be a useful large animal model for human cancer research. |
| Rights: | http://creativecommons.org/licenses/by/4.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/81069 |
| Appears in Collections: | 獣医学院・獣医学研究院 (Graduate School of Veterinary Medicine / Faculty of Veterinary Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
